Trial · NCT06848075
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
NCT06848075, Phase 2, Completed, TriGemX Bio, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine. Trials, record NCT06848075. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06848075
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
- NCT number
- NCT06848075
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 431 participants, actual
- Lead sponsor
- TriGemX Bio, Inc.
- Conditions
- Migraine
- Interventions
- Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo
- First posted
- 2025-02-26
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Freedom | 2 hours post-dose | Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) |
| Secondary | Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia) | 2 hours post-dose | Assessed using the number of evaluable participants that reported the absence of their MBS |
| Secondary | Pain Relief | 2 hours post-dose | Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1). |
| Secondary | Freedom From Photophobia | 2 hours post-dose | Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline. |
| Secondary | Freedom From Phonophobia | 2 hours post-dose | Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline. |
| Secondary | Freedom From Nausea | 2 hours post-dose | Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline. |
| Secondary | The Probability of Requiring Rescue Medication | 24 hours post-dose | Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy |
| Secondary | Sustained Pain Freedom | From 2 to 24 hours | Assessed using the number of participants that did not experience any headache pain through the time period of interest |
| Secondary | Sustained Pain Relief | From 2 to 24 hours | Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest. |
| Secondary | Sustained Pain Freedom | From 2 to 48 hours | Assessed using the number of participants that did not experience any headache pain through the time period of interest. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06848075
GET https://conductscience.org/api/trials/v1/NCT06848075/registered